109 related articles for article (PubMed ID: 3620827)
1. Strontium-89 radionuclide therapy: a dosimetric study using impulse response function analysis.
Blake GM; Gray JM; Zivanovic MA; McEwan AJ; Fleming JS; Ackery DM
Br J Radiol; 1987 Jul; 60(715):685-92. PubMed ID: 3620827
[TBL] [Abstract][Full Text] [Related]
2. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
Breen SL; Powe JE; Porter AT
J Nucl Med; 1992 Jul; 33(7):1316-23. PubMed ID: 1613572
[TBL] [Abstract][Full Text] [Related]
3. Strontium kinetics in metastasized prostatic carcinoma: a comparison with the predictions of impulse response function analysis.
Blake GM; Zivanovic MA; Gray JM
Nucl Med Commun; 1987 Nov; 8(11):909-19. PubMed ID: 3441327
[TBL] [Abstract][Full Text] [Related]
4. Strontium-89 therapy: strontium kinetics and dosimetry in two patients treated for metastasising osteosarcoma.
Blake GM; Zivanovic MA; McEwan AJ; Condon BR; Ackery DM
Br J Radiol; 1987 Mar; 60(711):253-9. PubMed ID: 3471288
[TBL] [Abstract][Full Text] [Related]
5. 89Sr therapy: strontium plasma clearance in disseminated prostatic carcinoma.
Blake GM; Wood JF; Wood PJ; Zivanovic MA; Lewington VJ
Eur J Nucl Med; 1989; 15(1):49-54. PubMed ID: 2537216
[TBL] [Abstract][Full Text] [Related]
6. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate.
Blake GM; Zivanovic MA; McEwan AJ; Ackery DM
Eur J Nucl Med; 1986; 12(9):447-54. PubMed ID: 3102236
[TBL] [Abstract][Full Text] [Related]
7. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases.
Blake GM; Zivanovic MA; Blaquiere RM; Fine DR; McEwan AJ; Ackery DM
J Nucl Med; 1988 Apr; 29(4):549-57. PubMed ID: 3351609
[TBL] [Abstract][Full Text] [Related]
8. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
Brundage MD; Crook JM; Lukka H
Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
[TBL] [Abstract][Full Text] [Related]
9. Measurements of the strontium plasma clearance rate in patients receiving 89Sr radionuclide therapy.
Blake GM; Zivanovic MA; Lewington VJ
Eur J Nucl Med; 1989; 15(12):780-3. PubMed ID: 2516486
[TBL] [Abstract][Full Text] [Related]
10. Influence of human biokinetics of strontium on internal ingestion dose of 90Sr and absorbed dose of 89Sr to organs and metastases.
Li WB; Höllriegl V; Roth P; Oeh U
Radiat Environ Biophys; 2008 Apr; 47(2):225-39. PubMed ID: 18204850
[TBL] [Abstract][Full Text] [Related]
11. [89Sr Therapy for pain relief in patients with bone metastases].
Koizumi K; Arbab AS; Toyama K; Shirasu M; Osawa S; Araki T; Yamaguchi M; Onishi H; Araki T; Arai T; Komatsu H; Ueno A; Nokata H
Kaku Igaku; 1996 Nov; 33(11):1243-8. PubMed ID: 8986064
[TBL] [Abstract][Full Text] [Related]
12. Bone pain palliation with 85Sr therapy.
Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
[TBL] [Abstract][Full Text] [Related]
13. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
Papatheofanis FJ
J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
[TBL] [Abstract][Full Text] [Related]
14. [Influence of 89Sr on the cell immune function in patients with multiple bone metastases].
Wu YG; Ma QL; Liu GF
Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):277-8. PubMed ID: 12575316
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with strontium-89 in prostatic and breast cancer patients.
Robinson RG; Preston DF; Baxter KG; Dusing RW; Spicer JA
Semin Oncol; 1993 Jun; 20(3 Suppl 2):44-8. PubMed ID: 8503027
[TBL] [Abstract][Full Text] [Related]
16. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy.
Tu SM; Kim J; Pagliaro LC; Vakar-Lopez F; Wong FC; Wen S; General R; Podoloff DA; Lin SH; Logothetis CJ
J Clin Oncol; 2005 Nov; 23(31):7904-10. PubMed ID: 16258090
[TBL] [Abstract][Full Text] [Related]
17. Radionuclide-targeted therapy for the management of metastatic bone pain.
Ackery D; Yardley J
Semin Oncol; 1993 Jun; 20(3 Suppl 2):27-31. PubMed ID: 7684862
[TBL] [Abstract][Full Text] [Related]
18. Autopsy of a cadaver containing strontium-89-chloride.
Schraml FV; Parr LF; Ghurani S; Silverman ED
J Nucl Med; 1997 Mar; 38(3):380-2. PubMed ID: 9074523
[TBL] [Abstract][Full Text] [Related]
19. Hematologic depression following therapy with strontium-89 chloride.
Cowan RJ; Chilton HM; Cooper MR; Ferree CR; Watson EE; Robinson RG
Clin Nucl Med; 1986 Dec; 11(12):845-6. PubMed ID: 2434277
[TBL] [Abstract][Full Text] [Related]
20. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.
Laing AH; Ackery DM; Bayly RJ; Buchanan RB; Lewington VJ; McEwan AJ; Macleod PM; Zivanovic MA
Br J Radiol; 1991 Sep; 64(765):816-22. PubMed ID: 1717094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
